PAR
PARADIGM BIO. ORDINARYParadigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
PAR
PAR
PARADIGM BIO. ORDINARY
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.01% | — |
| 24 Aug | 0.02% | — |
| 21 Aug | 0.08% | — |
| 20 Aug | 0.08% | — |
| 19 Aug | 0.08% | — |
| 18 Aug | 0.07% | — |
| 17 Aug | 0.08% | — |
| 14 Aug | 0.05% | — |
| 13 Aug | 0.00% | — |
Paradigm Bio (PAR) Short Interest Summary
Paradigm Bio (PAR) currently has 0.01% of its shares sold short (62 thousand shares, worth approximately $13K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes PAR the #573 most shorted stock on the ASX most shorted list. Short interest in PAR is down 0.06% over the past week and up 0.01% over the past month. PAR is part of the Health Care sector on the ASX.
Recent PAR Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.01% | 0.1M | $0.22 |
| 24 Aug 2026 | 0.02% | 0.1M | $0.20 |
| 21 Aug 2026 | 0.08% | 0.5M | $0.17 |
| 20 Aug 2026 | 0.08% | 0.5M | $0.17 |
| 19 Aug 2026 | 0.08% | 0.5M | $0.17 |
| 18 Aug 2026 | 0.07% | 0.4M | $0.18 |
| 17 Aug 2026 | 0.08% | 0.5M | $0.17 |
| 14 Aug 2026 | 0.05% | 0.3M | $0.18 |
| 13 Aug 2026 | 0.00% | 0.0M | $0.18 |
| 12 Aug 2026 | 0.00% | 0.0M | $0.17 |
PAR Short Selling — Frequently Asked Questions
What is Paradigm Bio (PAR)'s current short interest?
Paradigm Bio (PAR) currently has a short interest of 0.01% of total shares outstanding. This means 0.01% of PAR's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is PAR heavily shorted on the ASX?
PAR has a relatively low short interest of 0.01%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for PAR investors?
Short interest in PAR shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.01%, PAR's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this PAR short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for PAR.